The neurodegenerative disorder therapeutics market is projected to grow at a CAGR of 7.21% during the forecast period, 2020-2030. The market is estimated to be around $48.91 Billion by the end of 2020.
The global neoantigen cancer vaccine industry analysis by BIS Research projects the market to grow at a significant CAGR of 77.73% during the forecast period 2024-2031.
The Car T-Cell therapy market is projected to grow at the CAGR of 44.79% during the forecast period from 2020-2030. It is expected to reach $43.04 Billion by the end of 2030.
The Global Point-of-Care Imaging Devices Market was valued to be $8.66 billion in 2019 and is anticipated to witness an impressive double-digit growth rate, to reach $19.84 billion by 2030.
The global market for DNA damage response drugs is predicted to grow at a CAGR of 21.33% over the forecast period of 2020-2030. The market is driven by certain factors, which include the rising global prevalence of cancer, favorable reimbursement scenario, increasing oncology R&D expenditure, and an increase in the adoption of precision medicine in cancer treatment.
The global oncology precision medicine market was valued at $45,174.2 million in 2020 and is expected to reach $1,28,891.6 million by 2031, growing at a CAGR of 10.05% during the forecast period 2021-2031.
Table of Content - U.S. Prostate Cancer Testing Market.pdfBIS Research Inc.
The U.S. prostate cancer testing market is anticipated to reach $1,901.6 million in 2030 from $544.1 million in 2021, with a CAGR of 14.7%, during the forecast period 2022-2030.
The global female technology market was estimated at $560.5 million in 2018 and is expected to witness a sharp growth of 17.18% during the forecast period 2019-2030.
The somatic genetic testing market is expected to grow at a CAGR of 9.30% during the forecast period from 2020 to 2030. The market is projected to reach $16.79 billion by the end of 2030.
The global neoantigen cancer vaccine industry analysis by BIS Research projects the market to grow at a significant CAGR of 77.73% during the forecast period 2024-2031.
The Car T-Cell therapy market is projected to grow at the CAGR of 44.79% during the forecast period from 2020-2030. It is expected to reach $43.04 Billion by the end of 2030.
The Global Point-of-Care Imaging Devices Market was valued to be $8.66 billion in 2019 and is anticipated to witness an impressive double-digit growth rate, to reach $19.84 billion by 2030.
The global market for DNA damage response drugs is predicted to grow at a CAGR of 21.33% over the forecast period of 2020-2030. The market is driven by certain factors, which include the rising global prevalence of cancer, favorable reimbursement scenario, increasing oncology R&D expenditure, and an increase in the adoption of precision medicine in cancer treatment.
The global oncology precision medicine market was valued at $45,174.2 million in 2020 and is expected to reach $1,28,891.6 million by 2031, growing at a CAGR of 10.05% during the forecast period 2021-2031.
Table of Content - U.S. Prostate Cancer Testing Market.pdfBIS Research Inc.
The U.S. prostate cancer testing market is anticipated to reach $1,901.6 million in 2030 from $544.1 million in 2021, with a CAGR of 14.7%, during the forecast period 2022-2030.
The global female technology market was estimated at $560.5 million in 2018 and is expected to witness a sharp growth of 17.18% during the forecast period 2019-2030.
The somatic genetic testing market is expected to grow at a CAGR of 9.30% during the forecast period from 2020 to 2030. The market is projected to reach $16.79 billion by the end of 2030.
Global Emerging Sleep Apnea Devices and Platforms MarketBIS Research Inc.
The global emerging sleep apnea devices and platforms market is witnessing an exponential rise in the size of the market due to the ongoing COVID-19 pandemic. The overall market was estimated to be $4,882.2 million in FY2019, and it is expected to grow at a CAGR of 9.94% during the forecast period, 2021-2030.
The global oncology precision medicine market was valued at $46.90 billion in 2019, and it is expected to grow at an impressive double-digit rate of 11.21% and reach a value of $148.66 billion in 2030.
Cell and Gene Therapy Market - Growth Analysis & TrendsBIS Research Inc.
The cell and gene therapy industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast year 2019-25
DNA Methylation Market _ Industry Analysis & Report BIS Research Inc.
The current DNA methylation market is mainly dominated by several diagnostic majors, such as Exact Sciences Corporation, Illumina, Inc., QIAGEN N.V., and Thermo Fisher Scientific Inc., which offer a wide variety of diagnostics and research-based products for detection of DNA methylation in genomes.
The Non-invasive prenatal testing (NIPT) market is projected to reach $10,818.4 Million by 2030 from $2,182.3 Million in 2020, at a CAGR of 15.83% during the forecast period, 2020-2030.
The global NGS informatics market is projected to reach $6,715.0 million by 2032. The market is expected to grow at a CAGR of 15.21% during the forecast period 2022-2032.
The global healthcare service robots market was valued to be $462.3 million in 2019 and is anticipated to witness an impressive double-digit growth rate, to reach $2.82 billion by 2025.
The market size is expected to reach $12.9 Billion in 2030, from $ 2.58 Billion in 2019. The global liquid biopsy market is expected to grow at a robust rate of 15.87% during the forecast period, 2020-2030.
The global liquid biopsy market is projected to reach $12,933 million by 2030 and grow with a significant CAGR of 15.87%
get more detailed : https://bisresearch.com/industry-report/global-liquid-biopsy-market.html
The lung cancer genomic testing market was valued at $1,262.0 million in 2020 and is expected to reach $3,279.8 million by 2031, growing at a CAGR of 8.97% during the forecast period 2021-2031.
The purpose of the study is to gain a holistic view of the active plasma medicine projects implemented in several countries. The report contains the analysis of various such as recent trends, technological advancements, reimbursement scenario, and international level initiatives across the globe influencing the adoption of plasma medicine.
The global targeted sequencing market is projected to reach $10,976.1 million by 2032, growing at a CAGR of 13.12% during the forecast period 2022-2032.
The global precision medicine market is expected to reach $278.61 billion by the end of 2030. The market is projected to grow at a CAGR of 11.13% during the forecast period, 2020-2030.
The global precision medicine market is expected to reach $278.61 billion by the end of 2030. The market is projected to grow at a CAGR of 11.13% during the forecast period, 2020-2030.
Global Neurostimulation Devices Market - Global Industry AnalysisBIS Research Inc.
Neurostimulation devices consider the implantable and non-implantable neurostimulation devices which act on the spinal cord and brain to deliver the electrical stimulation to a targeted area.
Our healthcare experts have found COVID-19 Diagnostic Testing industry to be one of the most rapidly evolving and dynamic markets and the global market for COVID-19 diagnostic testing is predicted to grow at a CQGR of 23.50% over the forecast period of 3Q2020-4Q2021.
The global non-oncology precision medicine market was estimated at $41.1 Billion in 2019 and is projected to grow at a CAGR of 11.03% during the forecast period, 2020-2030.
The global sustainable steel market is projected to reach $795.8 billion by 2031 from $327.3 billion in 2021, growing at a CAGR of 8.97% during the forecast period 2022-2031. The growth in the global sustainable steel market is expected to be driven by stringent government regulations, carbon neutrality targets, energy and cost efficiency owing to the use of recycled steel, and a significant increase in steel demand with the scarcity of raw materials and energy.
More Related Content
Similar to Global Neurodegenerative Disorder Therapeutics Market
Global Emerging Sleep Apnea Devices and Platforms MarketBIS Research Inc.
The global emerging sleep apnea devices and platforms market is witnessing an exponential rise in the size of the market due to the ongoing COVID-19 pandemic. The overall market was estimated to be $4,882.2 million in FY2019, and it is expected to grow at a CAGR of 9.94% during the forecast period, 2021-2030.
The global oncology precision medicine market was valued at $46.90 billion in 2019, and it is expected to grow at an impressive double-digit rate of 11.21% and reach a value of $148.66 billion in 2030.
Cell and Gene Therapy Market - Growth Analysis & TrendsBIS Research Inc.
The cell and gene therapy industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast year 2019-25
DNA Methylation Market _ Industry Analysis & Report BIS Research Inc.
The current DNA methylation market is mainly dominated by several diagnostic majors, such as Exact Sciences Corporation, Illumina, Inc., QIAGEN N.V., and Thermo Fisher Scientific Inc., which offer a wide variety of diagnostics and research-based products for detection of DNA methylation in genomes.
The Non-invasive prenatal testing (NIPT) market is projected to reach $10,818.4 Million by 2030 from $2,182.3 Million in 2020, at a CAGR of 15.83% during the forecast period, 2020-2030.
The global NGS informatics market is projected to reach $6,715.0 million by 2032. The market is expected to grow at a CAGR of 15.21% during the forecast period 2022-2032.
The global healthcare service robots market was valued to be $462.3 million in 2019 and is anticipated to witness an impressive double-digit growth rate, to reach $2.82 billion by 2025.
The market size is expected to reach $12.9 Billion in 2030, from $ 2.58 Billion in 2019. The global liquid biopsy market is expected to grow at a robust rate of 15.87% during the forecast period, 2020-2030.
The global liquid biopsy market is projected to reach $12,933 million by 2030 and grow with a significant CAGR of 15.87%
get more detailed : https://bisresearch.com/industry-report/global-liquid-biopsy-market.html
The lung cancer genomic testing market was valued at $1,262.0 million in 2020 and is expected to reach $3,279.8 million by 2031, growing at a CAGR of 8.97% during the forecast period 2021-2031.
The purpose of the study is to gain a holistic view of the active plasma medicine projects implemented in several countries. The report contains the analysis of various such as recent trends, technological advancements, reimbursement scenario, and international level initiatives across the globe influencing the adoption of plasma medicine.
The global targeted sequencing market is projected to reach $10,976.1 million by 2032, growing at a CAGR of 13.12% during the forecast period 2022-2032.
The global precision medicine market is expected to reach $278.61 billion by the end of 2030. The market is projected to grow at a CAGR of 11.13% during the forecast period, 2020-2030.
The global precision medicine market is expected to reach $278.61 billion by the end of 2030. The market is projected to grow at a CAGR of 11.13% during the forecast period, 2020-2030.
Global Neurostimulation Devices Market - Global Industry AnalysisBIS Research Inc.
Neurostimulation devices consider the implantable and non-implantable neurostimulation devices which act on the spinal cord and brain to deliver the electrical stimulation to a targeted area.
Our healthcare experts have found COVID-19 Diagnostic Testing industry to be one of the most rapidly evolving and dynamic markets and the global market for COVID-19 diagnostic testing is predicted to grow at a CQGR of 23.50% over the forecast period of 3Q2020-4Q2021.
The global non-oncology precision medicine market was estimated at $41.1 Billion in 2019 and is projected to grow at a CAGR of 11.03% during the forecast period, 2020-2030.
Similar to Global Neurodegenerative Disorder Therapeutics Market (20)
The global sustainable steel market is projected to reach $795.8 billion by 2031 from $327.3 billion in 2021, growing at a CAGR of 8.97% during the forecast period 2022-2031. The growth in the global sustainable steel market is expected to be driven by stringent government regulations, carbon neutrality targets, energy and cost efficiency owing to the use of recycled steel, and a significant increase in steel demand with the scarcity of raw materials and energy.
Cybersecurity in Automotive Connected Vehicles and Growing Security Vulnerabi...BIS Research Inc.
• Agenda:
o To evaluate various security vulnerabilities in connected vehicles.
o To analyze the initiatives taken and regulations implemented to address security vulnerabilities.
o To analyze the various types of cybersecurity solutions being developed or offered for the security of connected vehicles.
o To evaluate the major players in the ecosystem.
Report Preview is available at: https://bisresearch.com/industry-report/global-automotive-cybersecurity-market.html
BIS Research conducted a webinar on Carbon Neutral Data Center PracticesBIS Research Inc.
Agenda:
To evaluate various emerging trends in Data center industry.
To analyze the initiatives taken and regulations implemented to increase sustainable practices.
To analyze the various types of technologies currently deployed.
To evaluate the major players in the ecosystem.
Speaker Profiles:
Name: JD Enright, Sr.
Designation: Chief Operating Officer
Company: TMGcore Inc.
Experienced and dedicated business professional with 29 years working with DOD, Multinational Private and Public sector organizations. Primary focus on developing and executing Strategic Step-Up Growth initiatives in Emerging Markets, and Technologies. Specialized leadership in developing improved business operations to include Financial and Operational efficiencies. Implementation of next generation HPC Platforms, Global Blockchain Development Strategies, Biotechnology, Viral Cell and Gene Therapies and Market Intelligence Assimilation for public applications.
Webinar by BIS Research on Precision Oncology BiomarkersBIS Research Inc.
Precision oncology biomarkers are essential tools for tailoring cancer treatment to individual patients, as they provide insights into tumor biology and guide the selection of targeted therapies.
BIS conducted a deep intelligence webinar on the state-of-the-art technologies and emerging strategies used through the precision oncology biomarkers.
Direct-to-Customer Wellness | A Webinar on the Growing Need for Personalized ...BIS Research Inc.
Direct-to-consumer (DTC) wellness testing industry witnessed a strong emphasis on consumer health and wellness, instigating industry stakeholders to discover new revenue streams.
As a leading market intelligence firm, BIS Research strives to stay on top of the latest emerging trends in the healthcare sector, among several other industry verticals. In the bid to do the same, BIS is conducting a deep intelligence webinar on the increasing focus of DTC wellness programs in the healthcare sector.
Read Related Reports Overview at:
https://bisresearch.com/industry-report/global-direct-to-consumer-genetic-testing-market.html
https://bisresearch.com/industry-report/us-dtc-wellness-testing-market.html
Emerging Battery Chemistries | Reimagining EVs Beyond Conventional Li-Ion Bat...BIS Research Inc.
The efficiency of the battery system in any electric vehicle (EV) determines its cost and vehicle performance. Challenges, such as range anxiety and charging time, have been a hindrance to increasing EV sales.
As a leading market intelligence firm, BIS Research strives to stay on top of the latest emerging technologies in the mobility sector, among several other industry verticals.
In the bid to do the same, BIS is conducting a deep intelligence webinar on the current paradigm shift happening for battery technologies in electric vehicles.
Here are all the details:
Webinar Topic: Emerging Battery Chemistries | Reimagining EVs Beyond Conventional Li-Ion Batteries
Webinar on AI in Medical Diagnosis with Emerging TechnologiesBIS Research Inc.
Artificial Intelligence (AI) is a rapidly growing field that has the potential to revolutionize the way medical diagnosis is performed. AI systems use advanced algorithms to analyze large amounts of data, such as medical images, patient histories, and lab results, to identify patterns and make predictions about patient outcomes.
In medical diagnosis, AI can be used in a variety of ways, including medical imaging, disease diagnosis, personalized treatment planning, and early disease detection. By leveraging the power of AI, healthcare providers can make faster and more accurate diagnoses, resulting in better patient outcomes.
Agenda:
The main agenda of this webinar is to understand and explore the following:
• Policy implications related to AI and digital transformation in healthcare.
• Initiatives taken and regulations implemented to address cybersecurity concerns.
• Major factors driving and hindering the growth of AI in medical devices diagnosis.
• Major players in the ecosystem
AI-Enabled Imaging Solutions Market - A Global Market Report by BIS ResearchBIS Research Inc.
The global AI-enabled medical imaging solutions market was valued at $1,854.5 million in 2022 and is anticipated to reach $18,356.5 million by 2032, witnessing a CAGR of 25.76% during the forecast period 2022-2032. you can get more info to visit this link..
https://bisresearch.com/industry-report/global-ai-enabled-medical-imaging-solutions-market.html
The global demand for achieving the net zero emission target by 2050 has pushed governments all over to adapt and adopt advanced carbon removal technologies to go carbon negative.
It is, indeed, an important topic of discussion, because a carbon free environment is the need of the hour to save our planet. And, therefore, BIS Research is glad to announce its upcoming webinar on this particular subject.
Agenda:
The main agenda of this webinar is to understand and explore the following:
• Primary sources of carbon emissions and associated environmental issues
• Carbon dioxide removal – key technology and adoption scenario
• Carbon dioxide removal (CDR): trends and key market developments
• Carbon dioxide removal as a credible solution
• Conclusion and future outlook
Webinar on Biomanufacturing 4.0 – A New Era in Cell and Gene Therapy DevelopmentBIS Research Inc.
Agenda of the Webinar:
Cell and Gene Therapy Biomanufacturing Market: Trends and Key Developments
Awaited Technologies in the Cell and Gene Therapy Development
Regulatory Scenario – GMP/cGMP Guidelines
Biomanufacturing 4.0 - Adoption Scenario
Conclusion and Future Outlook
Sub-Orbital Testing Services Market Future Growth and Business Opportunities ...BIS Research Inc.
Sub-orbital platforms are increasing access to the near space-like environment for end users such as government agencies, research institutions, and commercial players.
The competitive landscape of the sub-orbital testing services market consists of several organic and inorganic strategies followed by the key players to increase their market share.
The space industry is continuously innovating and developing advanced technologies with the objective of enhancing space capabilities. The industry is gearing up to develop vehicles that entail a major feature, i.e., reusability.
Request for the sample of the report at: https://bisresearch.com/requestsample?id=1442&type=download
TOC - Global Military Robotic and Autonomous Systems (RAS) Market.pdfBIS Research Inc.
The robotic and autonomous system (RAS) is a multidisciplinary scientific and technological domain for implementing complex systems with cognitive capabilities.
RAS in military is being rigorously introduced and used in combat training. This has boosted the capabilities of armed units and subunits. The advent of artificial intelligence (AI) and its integration with military RAS has the potential to change future warfare.
Growing demand to increase warfighter lethality and remove soldiers from dangerous situations is propelling the global military RAS market.
Request for the sample of the report at: https://bisresearch.com/requestsample?id=1442&type=download
UAV Propulsion System Market Analysis, Statistics, Regional, and Forecast to ...BIS Research Inc.
UAV propulsion system manufacturers have also been inclined to counter the environment and other government regulations by developing sustainable propulsion, i.e., steps toward fossil-free aviation fuels and ion propulsion are a few of such significant innovations.
UAVs can be powered by a variety of different types of engines, including piston engines, turbine engines, Wankel engines, and electric and solar-powered engines.
The global UAV propulsion system market has witnessed a high growth rate in the last five to six years owing to its widespread applications across various industries, which were further bolstered by the COVID-19 pandemic.
Publication of BIS Research on UAV Propulsion System market has some great insights for UAV Propulsion Systems. Get free sample here: https://bisresearch.com/requestsample?id=1443&type=download
Fleet Management Market Trends, Key Players, Industry Analysis and Forecast 2...BIS Research Inc.
A fleet management system, which includes hardware, software and service, has the ability to make decisions for fleet managers and fleet businesses easily.
The ongoing research and development activities in this market are experiencing product launches of fleet management system for fleet owners, fleet managers, or businesses that utilize fleet management on a daily basis.
BIS Research has a new publication on Fleet Management, view free sample here : https://bisresearch.com/requestsample?id=1444&type=download
Agenda:
The main agenda of this webinar is to understand and explore the following:
• LoRaWAN adoption in agricultural applications as well as understanding the trends and key market developments.
• The significance of LoRaWAN in the field of IoT
• A comparative analysis between LoRaWAN and other IoT networks in terms of technology and capabilities.
• The impact of LoRaWAN on the operations of the agriculture industry and common use cases.
• The impact of the implementation of LoRaWAN technology on stakeholders in the agriculture ecosystem.
• The potential challenges that LoRaWAN might face in the future.
• The competitiveness of the market for LoRaWAN technology.
Augmented Reality in Agriculture Analysis and Statistics from 2022-2027BIS Research Inc.
AR depicts superimposing visual, audio, or other sensory data onto the physical world to improve one's experience. It is one of the most popular technological trends in today’s times. AR images can be displayed on a variety of devices, including eyeglasses and goggles, headsets, and heads-up displays such as helmet visors. As more smartphones, tablets, and other handheld devices that support AR are becoming available globally, the most popular way to use AR is on these devices in a variety of apps and games.
Although AR is used to visually communicate information, it is the integration of AR with other technologies that make it possible to adapt to precision farming and visual-based operations. Hence, farmers can utilize AR in combination with other technologies such as artificial intelligence (AI), big data, and the Internet of Things (IoT) to manage the rising food demand.
Get Augmented Reality in Agriculture report overview at: https://bisresearch.com/industry-report/ar-agriculture-market.html
Smart Harvest Market Generated Opportunities, Future Scope 2022-2027BIS Research Inc.
The growth in the global smart harvest market is expected to be driven by increasing smart farming practices among farmers, labor shortage, and growing government support for promoting the use of smart tech in the agriculture industry. Supported by government policies and technological developments, farmers and growers across the globe are expected to increase the implementation of smart harvest technologies. Moreover, the smart harvest market is witnessing several upcoming trends and opportunities, further propelling growth in the industry.
Get the PDF document on the technical aspects of Smart Harvest Market at: https://bisresearch.com/requestsample?id=1386&type=download
Precision Pest Management Market Leading Players, Development and Demand Fore...BIS Research Inc.
While farmers are losing crops due to pests, they have pressure to increase food production to feed the growing world population.
Precision pest management (PPM) is very important to avoid destruction caused by pests and to increase productivity. PPM helps to detect pests early with the help of crop monitoring so they can be controlled early to avoid further losses. The availability of advanced technologies and equipment has made agriculture automation more prevalent in developed countries.
To know more about the in-depth insights on precision pest management market, get PDF document: https://bisresearch.com/requestsample?id=1404&type=download
Agriculture Drones and Robots Market Growth Opportunity, Trends, Demand Analy...BIS Research Inc.
Agriculture drones and robots offer multiple benefits over conventional farming equipment, which is another factor driving the demand for these products in the agriculture industry. The adoption of agriculture drones and robots in commercial farms offers huge cost-saving opportunities.
Request for the Sample of the Report at: https://bisresearch.com/requestsample?id=1425&type=download
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
India Diagnostic Labs Market: Dynamics, Key Players, and Industry Projections...Kumar Satyam
According to the TechSci Research report titled “India Diagnostic Labs Market Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2019-2029,” the India Diagnostic Labs Market was valued at USD 16,471.21 million in 2023 and is projected to grow at an impressive compound annual growth rate (CAGR) of 11.55% through 2029. This significant growth can be attributed to various factors, including collaborations and partnerships among leading companies, the expansion of diagnostic chains, and increasing accessibility to diagnostic services across the country. This comprehensive report delves into the market dynamics, recent trends, drivers, competitive landscape, and benefits of the research report, providing a detailed analysis of the India Diagnostic Labs Market.
Collaborations and Partnerships
Collaborations and partnerships among leading companies play a pivotal role in driving the growth of the India Diagnostic Labs Market. These strategic alliances allow companies to merge their expertise, strengthen their market positions, and offer innovative solutions. By combining resources, companies can enhance their research and development capabilities, expand their product portfolios, and improve their distribution networks. These collaborations also facilitate the sharing of technological advancements and best practices, contributing to the overall growth of the market.
Expansion of Diagnostic Chains
The expansion of diagnostic chains is a driving force behind the growing demand for diagnostic lab services. Diagnostic chains often establish multiple laboratories and diagnostic centers in various cities and regions, including urban and rural areas. This expanded network makes diagnostic services more accessible to a larger portion of the population, addressing healthcare disparities and reaching underserved populations. The presence of diagnostic chain facilities in multiple locations within a city or region provides convenience for patients, reducing travel time and effort. A broader network of labs often leads to reduced waiting times for appointments and sample collection, ensuring that patients receive timely and efficient diagnostic services.
Rising Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases is a significant driver for the demand for diagnostic lab services. Chronic conditions such as diabetes, cardiovascular diseases, and cancer require regular monitoring and diagnostic testing for effective management. The rise in chronic diseases necessitates the use of advanced diagnostic tools and technologies, driving the growth of the diagnostic labs market. Additionally, early diagnosis and timely intervention are crucial for managing chronic diseases, further boosting the demand for diagnostic lab services.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
This document is designed as an introductory to medical students,nursing students,midwives or other healthcare trainees to improve their understanding about how health system in Sri Lanka cares children health.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Global Neurodegenerative Disorder Therapeutics Market
1. All rights reserved at BIS Research
1
Global
Neurodegenerative
Disorder Therapeutics
Market
Focus on Product, Mechanism,
Route of Administration, Indication,
Country Data (14 Countries),
and Competitive Landscape:
Analysis and Forecast: 2019-2030
October 2020
TOC
3. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 3
Table of Contents
Executive Summary…………………………………………………………….20
1. Technology Definition.......................................................................................... 41
1.1 Inclusion and Exclusion Criteria................................................................ 41
1.1.1 Inclusions...................................................................................... 41
1.1.2 Exclusions .................................................................................... 42
2. Research Scope.................................................................................................... 43
2.1 Key Questions Answered in the Report.................................................... 45
3. Research Methodology ........................................................................................ 47
3.1 Neurodegenerative Disorder Therapeutics: Research Methodology ..... 47
3.2 Primary Data Sources................................................................................. 48
3.3 Secondary Data Sources............................................................................ 49
3.4 Market Estimation Model............................................................................ 49
3.5 Criteria for Company Profiling................................................................... 52
4. Market Overview................................................................................................... 53
4.1 Neurodegenerative Disorder Therapeutics and Its Clinical Importance 53
4.2 Neurodegenerative Disorder Therapeutics Development and
Commercialization Landscape................................................................... 55
4.3 Global Neurodegenerative Disorder Therapeutics Market and Growth
Potential, 2019-2030.................................................................................... 57
4.4 Pricing and Reimbursement Scenario....................................................... 58
4.5 Impact of Patent Expiry and Entry of Biosimilars on Market .................. 59
4.6 Impact of COVID-19 on Neurodegenerative Disorder Therapeutics
Market........................................................................................................... 61
5. Epidemiology of Neurodegenerative Disorder Therapeutics ........................... 64
6. Patent Landscape................................................................................................. 73
4. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 4
7. Market Dynamics.................................................................................................. 77
7.1 Overview ...................................................................................................... 77
7.2 Impact Analysis........................................................................................... 77
7.3 Drivers.......................................................................................................... 78
7.3.1 Rising Global Prevalence of Neurodegenerative Disorders..... 78
7.3.2 The Increase in Number of Geriatric Populations ..................... 80
7.3.3 Increasing Research Funding in Neurodegenerative Disorders
....................................................................................................... 81
7.3.4 Rising Awareness about Neurodegenerative Disorders........... 82
7.4 Restraints..................................................................................................... 82
7.4.1 High Failure Rate of Neurodegenerative Drugs in Clinical Trials
....................................................................................................... 82
7.4.2 Lack of Effective Drugs and Therapies ...................................... 83
7.5 Opportunities............................................................................................... 84
8. Industry Insights................................................................................................... 85
8.1 Overview ...................................................................................................... 85
8.2 Regulatory Scenario ................................................................................... 85
8.3 Legal Requirements and Frameworks in the U.S..................................... 87
8.3.1 Clinical Trial Authorization.......................................................... 87
8.3.2 Marketing Authorization .............................................................. 88
8.3.3 USFDA Guidelines for BLA Submission .................................... 90
8.3.4 Post-Authorization Regulations.................................................. 91
8.4 Legal Requirements and Frameworks in Europe ..................................... 91
8.4.1 EMA Biologics License Application Process............................. 93
8.4.2 Centralized Procedure ................................................................. 94
8.4.3 Decentralized Procedure ............................................................. 94
8.4.4 Mutual-Recognition Procedure ................................................... 94
8.4.5 National Procedure....................................................................... 95
8.5 Legal Requirements and Frameworks in Asia-Pacific ............................. 95
8.5.1 China ............................................................................................. 95
8.5.2 Japan............................................................................................. 96
5. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 5
8.6 Expedited Regulatory Designations Around the World........................... 97
8.7 Role of Regulatory Bodies and Consortium in Neurodegenerative
Disorder Therapeutics .............................................................................. 100
8.8 Regulatory Guidelines .............................................................................. 100
8.8.1 Terminology Applied in Current Regulatory Guidelines for
Development of Drugs to Treat Neurodegenerative Disorders
..................................................................................................... 100
8.8.2 Actionable Recommendations .................................................. 102
8.8.2.1 EU:.......................................................................................... 102
8.8.2.2 EU:.......................................................................................... 102
8.8.2.3 Both Regions: ......................................................................... 103
8.9 Regulatory Challenges ............................................................................. 103
8.10 Reimbursement and Market Access........................................................ 104
9. Global Neurodegenerative Disorder Therapeutics Market, by Product Type
($Million), 2019-2030........................................................................................... 106
9.1 Commercialized Therapeutics ................................................................. 106
9.1.1 Multiple Sclerosis....................................................................... 106
9.1.1.1 Tecfidera................................................................................. 106
9.1.1.2 Ocrevus................................................................................... 107
9.1.1.3 Gilenya.................................................................................... 107
9.1.1.4 Aubagio................................................................................... 108
9.1.1.5 Interferon (Avonex and Plegridy)............................................. 108
9.1.1.6 Tysabri .................................................................................... 109
9.1.1.7 Rebif........................................................................................ 109
9.1.1.8 Copaxone................................................................................ 110
9.1.1.9 Betaseron................................................................................ 110
9.1.1.10 Lemtrada................................................................................. 111
9.1.1.11 Mavenclad............................................................................... 111
9.1.1.12 Fampyra.................................................................................. 112
9.1.1.13 Ampyra.................................................................................... 112
9.1.1.14 Mayzent .................................................................................. 113
9.1.1.15 Vumerity.................................................................................. 113
10. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 10
13.4.4 South Korea................................................................................ 204
13.4.4.1 South Korea Neurodegenerative Disorder Therapeutics Market
(by Indication), 2019-2030 ...................................................... 205
13.4.5 Australia...................................................................................... 206
13.4.5.1 Australia Neurodegenerative Disorder Therapeutics Market (by
Indication), 2019-2030 ............................................................ 207
13.4.6 Rest-of-APAC.............................................................................. 208
13.4.6.1 RoAPAC Neurodegenerative Disorder Therapeutics Market (by
Indication), 2019-2030 ............................................................ 209
13.5 Latin America ............................................................................................ 210
13.5.1 Brazil............................................................................................ 213
13.5.1.1 Brazil Neurodegenerative Disorder Therapeutics Market (by
Indication), 2019-2030 ............................................................ 214
13.5.2 Mexico ......................................................................................... 215
13.5.2.1 Mexico Neurodegenerative Disorder Therapeutics Market (by
Indication), 2019-2030 ............................................................ 216
13.5.3 Rest-of-Latin America ................................................................ 217
13.5.3.1 RoLATAM Neurodegenerative Disorder Therapeutics Market (by
Indication), 2019-2030 ............................................................ 218
13.6 Rest-of-the-World...................................................................................... 219
14. Competitive Landscape ..................................................................................... 220
14.1 Key Developments and Strategies .......................................................... 220
14.1.1 Regulatory and Legal Developments........................................ 222
14.1.2 Partnerships, Alliances, and Business Expansions................ 222
14.1.3 M&A Activities ............................................................................ 223
14.1.4 Funding Activities ...................................................................... 224
14.2 Market Share Analysis.............................................................................. 225
15. Company Profiles............................................................................................... 227
15.1 Overview .................................................................................................... 227
15.2 AbbVie Inc.................................................................................................. 228
15.2.1 Company Overview .................................................................... 228
11. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 11
15.2.2 Role of AbbVie Inc. in Global Neurodegenerative Disorder
Therapeutics Market .................................................................. 228
15.2.3 Financials.................................................................................... 231
15.2.4 Key Insights about Financial Health of the Company............. 233
15.2.5 SWOT Analysis........................................................................... 234
15.3 Bayer AG.................................................................................................... 235
15.3.1 Company Overview .................................................................... 235
15.3.2 Role of Bayer AG in Global Neurodegenerative Disorder
Therapeutics Market .................................................................. 235
15.3.3 Financials.................................................................................... 236
15.3.4 Key Insight about Financial Health of the Company............... 238
15.3.5 SWOT Analysis........................................................................... 239
15.4 Biogen Inc.................................................................................................. 240
15.4.1 Company Overview .................................................................... 240
15.4.2 Role of Biogen Inc. in Global Neurodegenerative Disorder
Therapeutics Market .................................................................. 240
15.4.3 Financials.................................................................................... 244
15.4.4 Key Insights about Financial Health of the Company............. 246
15.4.5 SWOT Analysis........................................................................... 247
15.5 Bristol-Myers Squibb Company............................................................... 248
15.5.1 Company Overview .................................................................... 248
15.5.2 Role of Bristol Myers Squibb Company in Global
Neurodegenerative Disorder Therapeutics Market ................. 248
15.5.3 Financials.................................................................................... 250
15.5.4 Key Insights About Financial Health of the Company ............ 251
15.5.5 SWOT Analysis........................................................................... 252
15.6 C. H. Boehringer Sohn AG & Co. KG....................................................... 253
15.6.1 Company Overview .................................................................... 253
15.6.2 Role of C. H. Boehringer Sohn AG & Co. KG in Global
Neurodegenerative Disorder Therapeutics Market ................. 253
15.6.3 Financials.................................................................................... 255
15.6.4 Key Insight about Financial Health of the Company............... 257
15.6.5 SWOT Analysis........................................................................... 258
12. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 12
15.7 Eisai Inc...................................................................................................... 259
15.7.1 Company Overview .................................................................... 259
15.7.2 Role of Eisai Inc. in Global Neurodegenerative Disorder
Therapeutics Market .................................................................. 259
15.7.3 Financials.................................................................................... 262
15.7.4 Key Insight about Financial Health of the Company............... 265
15.7.5 SWOT Analysis........................................................................... 266
15.8 F. Hoffmann-La Roche Ltd. ...................................................................... 267
15.8.1 Company Overview .................................................................... 267
15.8.2 Role of F. Hoffmann-La Roche Ltd. in Global Neurodegenerative
Disorder Therapeutics Market................................................... 267
15.8.3 Financials.................................................................................... 270
15.8.4 Key Insights About Financial Health of the Company ............ 272
15.8.5 SWOT Analysis........................................................................... 273
15.9 GlaxoSmithKline plc ................................................................................. 274
15.9.1 Company Overview .................................................................... 274
15.9.2 Role of GlaxoSmithKline plc in Global Neurodegenerative
Disorder Therapeutics Market................................................... 274
15.9.3 Financials.................................................................................... 276
15.9.4 Key Insights about Financial Health of the Company............. 279
15.9.5 SWOT Analysis........................................................................... 280
15.10H. Lundbeck A/S........................................................................................ 281
15.10.1 Company Overview .................................................................... 281
15.10.2 Role of H. Lundbeck A/S in Global Neurodegenerative Disorder
Therapeutics Market .................................................................. 281
15.10.3 Financials.................................................................................... 283
15.10.4 Key Insight about Financial Health of the Company............... 285
15.10.5 SWOT Analysis........................................................................... 286
15.11Merck KGaA............................................................................................... 287
15.11.1 Company Overview .................................................................... 287
15.11.2 Role of Merck KGaA in Global Neurodegenerative Disorder
Therapeutics Market .................................................................. 287
15.11.3 Financials.................................................................................... 289
13. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 13
15.11.4 Key Insights About Financial Health of the Company ............ 291
15.11.5 SWOT Analysis........................................................................... 292
15.12Novartis AG ............................................................................................... 293
15.12.1 Company Overview .................................................................... 293
15.12.2 Role of Novartis AG in Global Neurodegenerative Disorder
Therapeutics Market .................................................................. 293
15.12.3 Financials.................................................................................... 295
15.12.4 Key Insights About Financial Health of the Company ............ 297
15.12.5 SWOT Analysis........................................................................... 298
15.13Pfizer Inc. ................................................................................................... 299
15.13.1 Company Overview .................................................................... 299
15.13.2 Role of Pfizer Inc. in Global Neurodegenerative Disorder
Therapeutics Market .................................................................. 299
15.13.3 Financials.................................................................................... 301
15.13.4 Key Insights About Financial Health of the Company ............ 304
15.13.5 SWOT Analysis........................................................................... 305
15.14Sanofi S.A. ................................................................................................. 306
15.14.1 Company Overview .................................................................... 306
15.14.2 Role of Sanofi SA in Global Neurodegenerative Disorder
Therapeutics Market .................................................................. 306
15.14.3 Financials.................................................................................... 309
15.14.4 Key Insights About Financial Health of the Company ............ 311
15.14.5 SWOT Analysis........................................................................... 312
15.15Teva Pharmaceutical Industries Ltd........................................................ 313
15.15.1 Company Overview .................................................................... 313
15.15.2 Role of Teva Pharmaceutical Industries Ltd. in Global
Neurodegenerative Disorder Therapeutics Market ................. 313
15.15.3 Financials.................................................................................... 315
15.15.4 Key Insight about Financial Health of the Company............... 317
15.15.5 SWOT Analysis........................................................................... 318
15.16UCB Pharma SA. ....................................................................................... 319
15.16.1 Company Overview .................................................................... 319
14. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 14
15.16.2 Role of UCB Pharma SA in Global Neurodegenerative Disorder
Therapeutics Market .................................................................. 319
15.16.3 Financials.................................................................................... 321
15.16.4 Key Insight about Financial Health of the Company............... 323
15.16.5 SWOT Analysis........................................................................... 324
15. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 15
List of Figures
Figure 1: Global Total Burden of Diseases by Cause ......................................................................30
Figure 2: Global Geriatric Population by Age...................................................................................31
Figure 3: Global Neurodegenerative Disorder Therapeutics Market................................................32
Figure 4: Impact Analysis.................................................................................................................33
Figure 5: Share of Key Developments and Strategies, June 2015-June 2020.................................35
Figure 6: Global Neurodegenerative Disorder Therapeutics Market (by Drug Class), 2019 and 2030
.........................................................................................................................................................36
Figure 7: Global Neurodegenerative Disorder Therapeutics Market (by Indication), 2019 and 2030
.........................................................................................................................................................37
Figure 8: Global Neurodegenerative Disorder Therapeutics Market (by Route of Administraton), 2019
and 2030..........................................................................................................................................38
Figure 9: Global Neurodegenerative Disorder Therapeutics Market (by Region), 2019-2030..........39
Figure 2.1: Global Neurodegenerative Disorder Therapeutics Market Segmentation......................43
Figure 3.1: Global Neurodegenerative Disorder Therapeutic Market Methodology .........................46
Figure 3.2: Primary Research Methodology.....................................................................................47
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis) ............................................................49
Figure 3.4: Top-Down Approach (Segment-Wise Analysis).............................................................49
Figure 4.1: Neurodegenerative Disorder Therapeutics Clinical Trial Landscape..............................53
Figure 4.2: Global Neurodegenerative Disorder Market 2019-2030.................................................57
Figure 4.3: Patent Expiry of Neurodegenerative Disorder Therapies...............................................59
Figure 4.4: Most Impacted Practices in the Treatment of Neurodegenerative Disorders .................61
Figure 5.1: Prevalence of Neurodegenerative Disorders in the U.S. (Total Population)...................64
Figure 5.2: Prevalence of Alzheimer’s Disease in the U.S. (Total Population).................................65
Figure 5.3: Prevalence of Epilepsy in the U.S. (Total Population)....................................................65
Figure 5.4: Prevalence of Parkinson’s Disease in the U.S. (Total Population).................................66
Figure 5.5: Prevalence of Multiple Sclerosis in the U.S. (Total Population)......................................66
Figure 5.6: Prevalence of Spinal Muscular Atrophy (SMA) in the U.S. (Total Population)................67
Figure 5.7: Prevalence of Huntington's Disease in the U.S. (Total Population)................................67
Figure 5.8: Target Population of Epilepsy in the U.S........................................................................69
16. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 16
Figure 5.9: Target Population of Alzheimer’s Disease in the U.S.....................................................69
Figure 5.10: Target Population of Multiple Sclerosis in the U.S. ......................................................70
Figure 5.11: Target Population of Parkinson’s Disease in the U.S...................................................70
Figure 5.12: Target Population of Huntington's Disease in the U.S..................................................71
Figure 6.1: Number of Patents Filed, Neurodegenerative Disorder Therapeutics/Drugs, January 2015-
December 2019...............................................................................................................................72
Figure 6.2: Number of Patents Filed, Multiple Sclerosis Therapeutics/Drugs, January 2015-December
2019.................................................................................................................................................73
Figure 6.3: Number of Patents Filed, Alzheimer’s Disease Therapeutics/Drugs, January 2015-
December 2019...............................................................................................................................74
Figure 6.4: Percentage of Patents Filed, By Patent Office, January 2015-December 2019.............75
Figure 7.1: Impact Analysis..............................................................................................................77
Figure 7.2: Global Total Burden of Diseases by Cause ...................................................................78
Figure 7.3: Global Geriatric Population by Age................................................................................80
Figure 8.1: Steps for Obtaining Marketing Authorization..................................................................88
Figure 8.2: USFDA Review Timeline ...............................................................................................89
Figure 8.3: EMA Review Timeline....................................................................................................92
Figure 9.1: Global Neurodegenerative Disorder Therapeutics Market (Tecfidera - Product Revenue),
2019-2030 .....................................................................................................................................105
Figure 9.2: Global Neurodegenerative Disorder Therapeutics Market (Ocrevus – Product Revenue),
2019-2030 .....................................................................................................................................106
Figure 9.3: Global Neurodegenerative Disorder Therapeutics Market (Gilenya – Product Revenue),
2019-2030 .....................................................................................................................................106
Figure 9.4: Global Neurodegenerative Disorder Therapeutics Market (Aubagio – Product Revenue),
2019-2030 .....................................................................................................................................107
Figure 9.5: Global Neurodegenerative Disorder Therapeutics Market (Interferon (Avonex and
Plegridy) – Product Revenue), 2019-2030.....................................................................................107
Figure 9.6: Global Neurodegenerative Disorder Therapeutics Market (Tysabri – Product Revenue),
2019-2030 .....................................................................................................................................108
Figure 9.7: Global Neurodegenerative Disorder Therapeutics Market (Rebif – Product Revenue),
2019-2030 .....................................................................................................................................108
17. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 17
Figure 9.8: Global Neurodegenerative Disorder Therapeutics Market (Copaxone – Product Revenue),
2019-2030 .....................................................................................................................................109
Figure 9.9: Global Neurodegenerative Disorder Therapeutics Market (Betaseron – Product Revenue),
2019-2030 .....................................................................................................................................109
Figure 9.10: Global Neurodegenerative Disorder Therapeutics Market (Lemtrada – Product
Revenue), 2019-2030....................................................................................................................110
Figure 9.11: Global Neurodegenerative Disorder Therapeutics Market (Mavenclad – Product
Revenue), 2019-2030....................................................................................................................110
Figure 9.12: Global Neurodegenerative Disorder Therapeutics Market (Fampyra – Product Revenue),
2019-2030 .....................................................................................................................................111
Figure 9.13: Global Neurodegenerative Disorder Therapeutics Market (Ampyra – Product Revenue),
2019-2030 .....................................................................................................................................111
Figure 9.14: Global Neurodegenerative Disorder Therapeutics Market (Mayzent – Product Revenue),
2019-2030 .....................................................................................................................................112
Figure 9.15: Global Neurodegenerative Disorder Therapeutics Market (Vumerity – Product Revenue),
2019-2030 .....................................................................................................................................112
Figure 9.16: Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue),
2019-2030 .....................................................................................................................................113
Figure 9.17: Global Neurodegenerative Disorder Therapeutics Market (Lyrica – Product Revenue),
2019-2030 .....................................................................................................................................114
Figure 9.18: Global Neurodegenerative Disorder Therapeutics Market (Vimpat – Product Revenue),
2019-2030 .....................................................................................................................................114
Figure 9.19: Global Neurodegenerative Disorder Therapeutics Market (Onfi – Product Revenue),
2019-2030 .....................................................................................................................................115
Figure 9.20: Global Neurodegenerative Disorder Therapeutics Market (Keppra – Product Revenue),
2019-2030 .....................................................................................................................................115
Figure 9.21: Global Neurodegenerative Disorder Therapeutics Market (Sabril – Product Revenue),
2019-2030 .....................................................................................................................................116
Figure 9.22: Global Neurodegenerative Disorder Therapeutics Market (Briviact – Product Revenue),
2019-2030 .....................................................................................................................................116
18. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 18
Figure 9.23: Global Neurodegenerative Disorder Therapeutics Market (Fycompa – Product
Revenue), 2019-2030....................................................................................................................117
Figure 9.24: Global Neurodegenerative Disorder Therapeutics Market (Banzel – Product Revenue),
2019-2030 .....................................................................................................................................117
Figure 9.25: Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue),
2019-2030 .....................................................................................................................................118
Figure 9.26: Global Neurodegenerative Disorder Therapeutics Market (Ebixa – Product Revenue),
2019-2030 .....................................................................................................................................119
Figure 9.27: Global Neurodegenerative Disorder Therapeutics Market (Namenda XR – Product
Revenue), 2019-2030....................................................................................................................119
Figure 9.28: Global Neurodegenerative Disorder Therapeutics Market (Namzaric – Product
Revenue), 2019-2030....................................................................................................................120
Figure 9.29: Global Neurodegenerative Disorder Therapeutics Market (Galantamine – Product
Revenue), 2019-2030....................................................................................................................120
Figure 9.30: Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue),
2019-2030 .....................................................................................................................................121
Figure 9.31: Global Neurodegenerative Disorder Therapeutics Market (Azilect – Product Revenue),
2019-2030 .....................................................................................................................................122
Figure 9.32: Global Neurodegenerative Disorder Therapeutics Market (Neupro – Product Revenue),
2019-2030 .....................................................................................................................................122
Figure 9.33: Global Neurodegenerative Disorder Therapeutics Market (Madopar – Product Revenue),
2019-2030 .....................................................................................................................................123
Figure 9.34: Global Neurodegenerative Disorder Therapeutics Market (Duopa – Product Revenue),
2019-2030 .....................................................................................................................................123
Figure 9.35: Global Neurodegenerative Disorder Therapeutics Market (Inbrija – Product Revenue),
2019-2030 .....................................................................................................................................124
Figure 9.36: Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue),
2019-2030 .....................................................................................................................................124
Figure 9.37: Global Neurodegenerative Disorder Therapeutics Market (Spinraza – Product Revenue),
2019-2030 .....................................................................................................................................125
27. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 27
Figure 15.84: UCB Pharma SA: Overall Financials, 2017-2019.....................................................320
Figure 15.85: UCB Pharma SA: Revenue (by Product), 2017-2019..............................................321
Figure 15.86: UCB Pharma SA: Revenue (by Region), 2017-2019...............................................322
Figure 15.87: UCB Pharma SA: R&D Expenditure, 2017-2019 .....................................................322
Figure 15.88: UCB Pharma SA: SWOT Analysis...........................................................................323
28. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 28
List of Tables
Table 1: Leading Players in Global Neurodegenerative Disorder Therapeutics Market...................35
Table 4.1: Comparison of Drug Development Within and Outside the Central Nervous System .....54
Table 4.2: Commercialized Neurodegenerative Disorders Therapeutic Products............................55
Table 8.1: Regulatory Scenario Across the World ...........................................................................85
Table 8.2: Expedited Regulatory Designations Around the World ...................................................98
Table 8.3: Current Regulatory Development Guidelines for Neurodegenerative Disorders ...........101
Table 15.1: AbbVie Inc.: Pipeline Product Portfolio........................................................................230
Table 15.2: Biogen Inc.: Pipeline Product Portfolio ........................................................................242
Table 15.3: Bristol Myers Squibb Company: Pipeline Product Portfolio.........................................249
Table 15.4: C. H. Boehringer Sohn AG & Co. KG Company: Pipeline Product Portfolio................254
Table 15.5: C. H. Boehringer Sohn AG & Co. KG Company: Pipeline Product Portfolio................261
Table 15.6: F. Hoffmann-La Roche Ltd.: Pipeline Product Portfolio...............................................268
Table 15.7: H. Lundbeck A/S Company: Pipeline Product Portfolio...............................................283
Table 15.8: Merck KGaA: Pipeline Product Portfolio......................................................................288
Table 15.9: Novartis AG: Pipeline Product Portfolio.......................................................................294
Table 15.10: Pfizer Plc: Pipeline Product Portfolio.........................................................................300
Table 15.11: Sanofi SA: Pipeline Product Portfolio........................................................................307
Table 15.12: Teva Pharmaceutical Industries Ltd Company: Pipeline Product Portfolio................315
Table 15.13: UCB Pharma SA Company: Pipeline Product Portfolio.............................................321
29. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 29
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in
today’s digital age. We have a vision to be a leading and a preferred knowledge partner for corporates
and institutions worldwide and assist them with market intelligence in the area of emerging
technologies, advisories, and other innovative solutions.
Know More Know More
Know More
Know More
30. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 30
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in
response to orders. The report is licensed for the customer's internal use only and is subject to
restrictions set henceforth. This document and its contents are confidential and may not be further
distributed, published or reproduced, in whole or in part, by any medium or in any form for any
purpose, without the written consent of BIS Research. The customer will not disclose the contents of
the report, whether directly through any medium or indirectly through incorporation in a database,
marketing list, report or otherwise, or use or permit the use of information to generate any statistical
or other information that is or will be provided to third parties, or voluntarily produce information in
legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information
is available. Any recommendation contained in this report may not be suitable for all investors or
businesses. The market conclusions drawn are necessarily based upon a number of estimates and
assumptions that, while considered reasonable by BIS Research as of the date of such statements,
are inherently subject to market fluctuations and business, economic and competitive uncertainties
and contingencies
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135
31. Global Neurodegenerative Disorder Therapeutics Market
All rights reserved at BIS Research 31
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: info@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544